Older adults with gastrointestinal cancers who had inadequate emotional support were more likely to have poor physical and mental health-related quality of life, in addition to depression, compared to those […]
Imugene Ltd (ASX:IMU, OTC:IUGNF) has presented new and significant data on HER-Vaxx at the World Congress of Gastrointestinal Cancer in Barcelona. Read More>
Merck’s cancer star Keytruda could be on its way to an updated label in HER2-positive stomach cancer after showing it can stave off tumor progression in a combination study. Read […]
Gastric cancer ranks as the fourth leading cause of cancer-related deaths worldwide and the third in China. The overall five-year survival rate stands at approximately 20%. Radical gastrectomy has emerged […]
Summary Patients with upper GI cancers are in dire need of new therapeutic options. Astellas is sitting on a shoo-in approval for a brand new targeted therapy based on highly […]
CLAUDIN-18 Splice Variant 2 (claudin-18.2; CLDN18.2) has become a promising target for the treatment of patients with digestive malignancies, such as gastric cancer (GC), gastroesophageal junction (GEJ) cancer, esophageal cancer, […]
The FDA has granted orphan drug designation to ATG-022, a Claudin 18.2 (CLDN18.2) antibody-drug conjugate (ADC), for the treatment of patients with gastric cancer and pancreatic cancer, according to a […]
Treatment with avelumab (Bavencio) plus GEN-001 in patients with advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma has demonstrated positive antitumor activity, according to an announcement by Genome & Company.1 The […]
Chinese biotechnology company CARsgen Therapeutics has started a Phase II clinical trial of CT041 in the US, enrolling patients with Claudin18.2 (CLDN18.2) positive advanced gastric cancer/gastroesophageal junction cancer (GC/GEJ). CT041 […]
A treatment currently under review by the Food and Drug Administration (FDA) for the treatment of patients with advanced unresectable or metastatic gastric or gastroesophageal junction (G/GEJ) adenocarcinoma has been […]
